Research Departments & Organizations
My lab has a strong translational theme and has two main directions: 1) development of new quantitative approaches to pathology and their use to classify tumors by prognosis or predict response to cancer therapy (cancer tissue biomarker research); and 2) the molecular analysis of growth factor receptors and signaling. Studies fall into 3 groups. Group 1: translational studies using tissue microarray technology and AQUA (automated quantitative analysis) applying basic molecular observations and tools to diagnostic problems in pathology. Main topics include predicting response to therapy in breast cancer and predicting metastasis in breast cancer and melanoma. Group 2: the examination of mechanisms of signaling by Met, (the HGF/SF receptor), ErbB family members and other receptor tyrosine kinases (RTK) in epithelial tumors. We are particularly interested in translocation of these receptors to the nucleus. Finally, Group 3: the use of spectral/spatial analysis tools to improve diagnostic accuracy in cytopathology.
Specialized Terms: Quantitative Pathology; Cancer Tissue Biomarkers; Melanoma; Breast Cancer; Cell-cell adhesion in cancer; Translation of molecular techniques to diagnostic cytopathology; General Cytopathology; Immunohistochemistry; thyroid pathology
Extensive Research Description
100% of Dr. Rimm’s lab efforts are related to cancer. He has largely focused on tissue biomarker
research. His most innovative research
has involved construction of patient cohorts using the tissue microarray format
and the development of methods for quantitative analysis of protein expression
on tissue microarrays and whole tissue sections. He was the lead author on a recent paper in
Journal of Clinical Oncology that sets forth guidelines for construction of
tissue microarrays from cooperative group clinical trial samples. This
expertise has landed him positions on correlative science committees in the
ALTTO and TEACH breast cancer clinical trials.
He has also published extensively in the field of biospecimen science
including a series of papers published in Laboratory Investigation, the most
popular being cited over 500 times. He is a
regular invited speaker at the Biospecimen Research Network annual meeting and
is supported by a large contract from the Office of Biospecimen and
Biorepository Research. However, his
most innovative efforts have been related to automated quantitative analysis of
formalin fixed, paraffin embedded tissue.
He and his lab developed the AQUA method of quantitative immunofluorescence
that was published in 2002 in Nature Medicine (over 350 citations). This
technology attempted to remove the subjectivity from the analysis of
immunohistochemistry specimens by using co-localization to define regions of
interest, rather than feature extraction of pathologist defined subregions.
There are over 100 publications in the literature from labs in the US and
around the world that use this technology, including many in high impact
journals (NEJM, Nature, Cancer Cell, JCO, etc). The technology has been patented and was the
founding intellectual property of HistoRx in 2004. The company has largely used the technology
to assist pharmaceutical companies in development of companion
|Lung||Determining Mechanisms of Sensitivity and Resistance to Anti-Cancer Therapy for Advanced Lung Cancer|
A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1.
Gaule P, Smithy JW, Toki M, Rehman J, Patell-Socha F, Cougot D, Collin P, Morrill P, Neumeister V, Rimm DL. A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1. JAMA Oncology 2017, 3:256-259. 2017
A proposal for validation of antibodies.
Uhlen M, Bandrowski A, Carr S, Edwards A, Ellenberg J, Lundberg E, Rimm DL, Rodriguez H, Hiltke T, Snyder M, Yamamoto T. A proposal for validation of antibodies. Nature Methods 2016, 13:823-7. 2016
Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells.
Welsh AW, Moeder CB, Kumar S, Gershkovich P, Alarid ET, Harigopal M, Haffty BG, Rimm DL. Standardization of estrogen receptor measurement in breast cancer suggests false-negative results are a function of threshold intensity rather than percentage of positive cells. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2011, 29:2978-84. 2011
Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues.
Rimm DL, Nielsen TO, Jewell SD, Rohrer DC, Broadwater G, Waldman F, Mitchell KA, Singh B, Tsongalis GJ, Frankel WL, Magliocco AM, Lara JF, Hsi ED, Bleiweiss IJ, Badve SS, Chen B, Ravdin PM, Schilsky RL, Thor A, Berry DA. Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2011, 29:2282-90. 2011
Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis.
Gould Rothberg BE, Bracken MB, Rimm DL. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. Journal Of The National Cancer Institute 2009, 101:452-74. 2009
What brown cannot do for you.
Rimm DL. What brown cannot do for you. Nature Biotechnology 2006, 24:914-6. 2006
Algorithms for Automated Tissue Microarray Analysis Reveal Novel Disease Sub-classifications.
Camp, R.L. Chung, G.G., and Rimm, D.L. (2002) Algorithms for Automated Tissue Microarray Analysis Reveal Novel Disease Sub-classifications. Nature Medicine 8(11):1323-8 2002